Document is current
Any future updates will be listed below
-
Authors
Morgan, Gilbert C.
Gregory, Andrew
Tang, Chengyun
Hwang, Sung Hee
Border, Jane J.
Xu, Jing
Liu, Yedan
Bai, Shan
Lee, Tae Jin
Cantwell, Cameron
Bunn, David
Wagner, Karen M.
Morisseau, Christophe
Pittman, Carly
Ngo, Alina
Osayi, Peter
Pabbidi, Aditi
O’Herron, Philip
Bagi, Zsolt
Filosa, Jessica A.
Yu, Hongwei
McReynolds, Cindy
Hammock, Bruce D.
Roman, Richard J.
-
Funding
Funding for this research was provided by:
National Institute of Health (AG079336)
National Institute of Health (AG079336)
National Institute of Health (P20GM104357)
National Institute of Health (R35ES030443)
National Institute of Health (U54NS127758)
National Institute of Health (NS126920)
National Institute of Health (AG057842)
National Institute of Health (P42ES004699)
National Institute Health (AG057842)
American Heart Association (25PRE1365157)
Physiology Faculty Startup Fund from Augusta University (TRIBA)
Harrington Brain Health Medicine Scholar Award (A25-1690)
- License Information
-
More Information
Article History
Received: 29 November 2025
Accepted: 26 January 2026
First Online: 6 February 2026
Declarations
:
: Not applicable.
: B.D. Hammock and C. McReynolds are founders, and S.H. Hwang is an employee of EicOsis L.L.C., a startup company with an sEH inhibitor in human clinical trials. B.D. Hammock, C. Morisseau, K. Wagner, and S.H. Hwang are inventors on patents owned by the University of California for the preparation and usage of dual sEH/COX-2 inhibitors.
